Company Overview

Aurinia Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of therapies for autoimmune and inflammatory diseases. Historically, the company operated within the biopharmaceutical and specialty pharmaceuticals industries, with a primary emphasis on rare and severe autoimmune conditions affecting the kidneys. Its core value proposition centered on developing targeted immunomodulatory therapies intended to address significant unmet medical needs.

The company’s primary product and revenue driver was LUPKYNIS® (voclosporin), an oral calcineurin inhibitor approved for the treatment of adult patients with active lupus nephritis. Aurinia’s strategic positioning was defined by its specialization in nephrology-focused autoimmune disease, a limited-competition market with high clinical complexity. Founded in 2011 through the merger of Aurinia Pharmaceuticals and Vifor Pharma’s Aspreva Pharmaceuticals development assets, the company evolved from a clinical-stage developer into a commercial-stage organization prior to its acquisition.

Business Operations

Aurinia’s business operations were historically organized around a single commercial segment focused on lupus nephritis therapeutics, supported by clinical development and medical affairs functions. Revenue generation was driven almost entirely by U.S. sales of LUPKYNIS®, following its FDA approval, with commercialization supported by a specialized sales force targeting nephrologists and rheumatologists.

The company maintained internal capabilities across clinical development, regulatory affairs, and commercialization, while manufacturing relied on third-party contract manufacturers. Aurinia also held global rights to voclosporin, including intellectual property and regulatory exclusivity. Following its acquisition by Alexion Pharmaceuticals, a subsidiary of AstraZeneca, Aurinia’s operations were integrated into Alexion’s rare disease business, and it ceased operating as an independent public company.

Strategic Position & Investments

Prior to its acquisition, Aurinia’s strategic direction was centered on maximizing the commercial potential of LUPKYNIS® in the United States and pursuing regulatory approvals in additional international markets. Growth initiatives included lifecycle management, post-marketing clinical studies, and evaluation of voclosporin in other autoimmune indications. The company did not maintain a broad pipeline beyond voclosporin, reflecting a concentrated asset strategy.

In 2023, Aurinia was acquired by Alexion Pharmaceuticals in an all-cash transaction, representing a strategic investment by Alexion to strengthen its portfolio in immunology and nephrology within the rare disease space. Post-acquisition, Aurinia became a wholly owned subsidiary, and its assets and ongoing studies were absorbed into Alexion’s global development and commercialization infrastructure.

Geographic Footprint

Historically, Aurinia was headquartered in Canada, with its corporate office in Victoria, British Columbia, and maintained significant operational presence in the United States, where its primary commercial activities occurred. The U.S. market represented the majority of revenue and strategic focus due to the FDA approval of LUPKYNIS®.

Internationally, Aurinia pursued regulatory and commercialization strategies in Europe and other global markets, primarily through partnerships and regulatory filings rather than direct sales infrastructure. Following the acquisition, the company’s geographic footprint and market influence expanded indirectly through Alexion’s established global operations across North America, Europe, and Asia-Pacific.

Leadership & Governance

Before its acquisition, Aurinia was led by an executive team with experience in rare disease drug development and commercialization. Governance followed a public-company structure with oversight from an independent board of directors until the company was taken private through the acquisition.

Key executives prior to acquisition included:

• Peter Greenleaf – President and Chief Executive Officer
• Joseph M. Miller – Chief Financial Officer
• Gregory A. Keenan – Chief Commercial Officer
• Michael A. Martin – Chief Operating Officer
• Richard A. Glickman – Chief Medical Officer

The leadership philosophy emphasized disciplined capital allocation, scientific rigor, and focused execution in niche therapeutic markets. Following the acquisition, executive oversight transitioned to Alexion Pharmaceuticals management, and Aurinia no longer maintains an independent leadership or governance structure.